Shopping Cart (Login required)

Biotage Introduces the New Advancer® Kilobatch for Automated Batch Sequencing at ACS Spring 2008

19 March 2008

(March 18, 2008) Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announces the introduction of the new Advancer® Kilobatch large-scale automated sequential batch microwave synthesizer. This new system is designed for safe and scalable production of up to kilogram quantities of material and will be showcased exclusively on booth #1611 at ACS Spring 2008, New Orleans.

Biotage Introduces the New Advancer® Kilobatch for Automated Batch Sequencing at ACS Spring 2008

(March 18, 2008) Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announces the introduction of the new Advancer® Kilobatch large-scale automated sequential batch microwave synthesizer. This new system is designed for safe and scalable production of up to kilogram quantities of material and will be showcased exclusively on booth #1611 at ACS Spring 2008, New Orleans.

The Advancer Kilobatch from Biotage is designed to address fast and reliable microwave scale-up without requiring re-optimization, resulting in significant time savings for users. Unlike traditional microwave batch and flow reactors, the Advancer Kilobatch is capable of processing both heterogeneous and homogenous reaction mixtures in automated batch-sequencing mode. Safe, reliable and easy to use, the Advancer Kilobatch operates at the high temperatures and pressures required for microwave chemistry.

Also presented on booth #1611 will be the latest ranges of SNAP cartridges from Biotage. The unique KP-NH SNAP cartridges are designed to purify organic amine reaction mixtures by flash purification. The innovative KP-NH chemistry shields organic amines from silanols, improving separations while eliminating the need for DCM and competing amines in gradients. The new SNAP KP-C18-HS from Biotage are reversed-phase flash cartridges designed to provide high sample-load purification of polar and ionizable compounds. Unlike conventional amino cartridges, both the SNAP KP-NH and the SNAP KP-C18-HS from Biotage offer seven sample loading options including internal dry loading with and without Samplet cartridges.

Biotage will also demonstrate the latest addition to the innovative EVOLUTE® sample preparation range on booth #1611. EVOLUTE CX is a mixed-mode resin-based SPE sorbent for the extraction of basic drugs from biological fluids using a generic procedure, minimizing method development time for bioanalysts. EVOLUTE CX removes protein, phospholipids, and salt interferences, delivering cleaner extracts with high reproducibility for accurate quantitation and trouble-free analyses through pre-clinical and clinical trials.

For more information on Biotage’s EVOLUTE CX sample preparation products, please visit booth #1611 at ACS Spring 2008, from 6-10 April 2008. Alternatively please email product_info@biotage.com or visit www.biotage.com


-ENDS-
For further press information please contact: Eleanor CallanMonk, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: biotage@scottpr.com

About Biotage
Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005 operations and products were acquired from the American company Argonaut, further strengthening the medicinal chemistry product range. The customers include the worlds top 30 pharmaceutical companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several other European countries. Biotage has 336 employees and had sales of 496,4 MSEK in 2007. Biotage is listed on the OMX Nordic Exchange Stockholm AB. Website: www.biotage.com

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as \"believe,\" \"expect,\" \"intend,\" and \"should,\" among others. These forward-looking statements are based on Biotage’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a \"safe harbor\" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage’s products (including seasonal fluctuations), difficulties in successfully adapting the Company’s products to integrated solutions and producing such products, and the Company’s ability to identify and develop new products and to differentiate its products from competitors.